Dust settled! Takeda pharmaceutical officially announced the completion of the acquisition of shire

[chinapharma.com news] on January 8, Takeda Pharmaceutical Co., Ltd (hereinafter referred to as "Takeda pharmaceutical") It announced the completion of the acquisition of shire (hereinafter referred to as "shire"), which took nearly eight months from the announcement of the transaction to the completion of the transaction Takeda pharmaceutical has become one of the top ten pharmaceutical companies in the world by virtue of the acquisition It is understood that Takeda Pharmaceutical (89.1%) and (formerly) shire (99.8%) have received strong support from shareholders for this acquisition Currently, the company's integration plan is going smoothly, and both sides will work together to build a global biopharmaceutical company headquartered in Japan, based on value and driven by R & D Takeda pharmaceutical is expanding its business coverage and maintaining an attractive position in Japan and the United States, and its employees around the world are committed to providing innovative drugs to about 80 countries or regions Takeda pharmaceutical focuses on the research of cancer, digestion, neuroscience and rare diseases, and promises to invest in research and development of blood products (PDT) and vaccines Takeda pharmaceutical's robust and highly innovative R & D engine will focus more on the innovation of breakthrough therapies and create a more global, stable and diversified product pipeline Mr Shan Guohong, head of Takeda pharmaceutical China, said in an interview during the 11th Health China Forum: "the main business of Takeda pharmaceutical after the merger will focus on six core areas, including cancer, digestion, neuroscience, rare diseases, blood products (PDT), vaccines, etc In terms of new drugs, the annual investment in new drug research and development will exceed 4 billion US dollars In the next five years, Takeda pharmaceutical will have more than 10 new drugs on the market " Mr Christophe Weber, global president and executive officer of Takeda pharmaceutical, said: "the integration work starts today We are confident that under the leadership of the experienced Takeda pharmaceutical executive team, we can successfully complete the integration and achieve outstanding results In September 2018, our business model set a clear framework for the integration plan, and we formed an experienced professional integration team to lead the whole process "